Abstract:Tau and ɑ-synuclein aggregates are the main histopathological hallmarks present in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders. Intraneuronal hyperphosphorylated tau accumulation is significantly connected to the degree of cognitive impairment in AD patients. In particular, the longest 2N4R tau isoform has a propensity to rapidly form oligomers and mature fibrils. On the other hand, misfolding of ɑ-synuclein (α-syn) is the characteristic feature in PD and dementia with Lewy bodies (DLB). There is a strong crosstalk between the two prone-to-aggregation proteins as they coprecipitated in some brains of AD, PD, and DLB patients. Simultaneous targeting of both proteinaceous oligomers and aggregates is still challenging. Here, we rationally designed and synthesized benzothiazole- and indole-based compounds using the structural hybridization strategy between the benzothiazole N744 cyanine dye and the diphenyl pyrazole Anle138b that showed anti-aggregation activity towards 2N4R tau and ɑ-syn, respectively. The anti-aggregation effect of the prepared compounds was monitored using the thioflavin-T (ThT) fluorescence assay, while transmission electron microscopy (TEM) was employed to detect fibrils upon the completion of a time-course study with the ThT assay. Moreover, the photo-induced crosslinking of unmodified protein (PICUP) assay was used to determine the formation of oligomers. Specifically, compounds 46 and 48 demonstrated the highest anti-aggregation activity by decreasing the ThT fluorescence to 4.0 and 14.8%, respectively, against ɑ-synuclein. Although no noticeable effect on 2N4R tau oligomers, 46 showed promising anti-oligomer activity against ɑ-syn. Both compounds induced a significantly high anti-aggregation effect against the two protein fibrils as visualized by TEM. Moreover, compound 48 remarkably inhibited α-syn inclusion and cell confluence using M17D cells. Collectively, compounds 46 and 48 could serve as a basic structure for further optimization to develop clinically active AD and PD disease-modifying agents.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to develop small - molecule compounds that can simultaneously inhibit the aggregation of tau protein (especially the 2N4R isoform) and α - synuclein (α - syn). Abnormal aggregation of tau protein and α - synuclein are the main pathological features of neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) respectively. By designing and synthesizing compounds based on benzothiazole and indole derivatives, researchers aim to find dual - target inhibitors that can effectively inhibit the aggregation of these two proteins, thus providing new candidate drugs for the treatment of these diseases. Specifically, through the structural hybridization strategy, researchers combined the structural characteristics of the benzothiazole dye N744 with anti - aggregation activity against 2N4R tau and the diphenylpyrazole Anle138b with anti - aggregation activity against α - syn, and designed and synthesized multiple compounds. The experimental results show that compounds 46 and 48 exhibit significant anti - aggregation activity in vitro, can effectively reduce the formation of α - syn fibrils, and also have a significant inhibitory effect on 2N4R tau fibrils. In addition, compound 48 also shows the ability to significantly reduce the formation of α - syn inclusions in cell experiments. In summary, the goal of this research is to provide potential treatment strategies for neurodegenerative diseases such as AD and PD through rational design and synthesis of new small - molecule compounds.

Discovery of small molecule benzothiazole and indole derivatives tackling tau 2N4R and a-synuclein fibrils